Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

IL-10 polymorphisms and prostate cancer risk: a meta-analysis

Prostate Cancer and Prostatic Diseases volume 14, pages 129–135 (2011)Cite this article

Subjects

Abstract

Evidence is accumulating that chronic inflammation may have an important role in prostate cancer (PCa). Three common polymorphisms in the promoter of interleukin-10 (IL-10) gene, −1082 A>G, −819 C>T and −592 C>A, have been implicated to alter the risk of PCa, but the results of relative studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed an updated meta-analysis on the basis of 10 studies. A comprehensive search was conducted to examine all the eligible studies of IL-10 polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) give a sense of the precision of the estimate. Overall, there were no significant associations between increased risk of PCa and IL-10 −1082 A>G, −819 C>T and −592 C>A polymorphisms. However, meta-analysis suggested that IL-10 −819 C>T and −592 C>A polymorphisms might be modestly associated with PCa aggressiveness (T versus C, OR=1.162, 95% CI: 1.035–1.305, P=0.011; A versus C, OR=1.131, 95% CI: 1.012–1.264, P=0.030; respectively). IL-10 −819 C>T and −592 C>A polymorphisms might impact PCa progression. Variant alleles at both −819 and −592 were modestly associated with advanced stages of PCa. Additional well-designed studies are warranted to validate these findings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106–130.

    Article  PubMed  Google Scholar 

  2. Schaid DJ . The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 (Spec 1): 103–121.

    Article  Google Scholar 

  3. Bosland MC . The role of steroid hormones in prostate carcinogenesis. JNatl Cancer Inst Monogr 2000; 27): 39–66.

    Article  Google Scholar 

  4. Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ et al. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 2010; 202: 76–81.

    Article  CAS  PubMed  Google Scholar 

  5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.

    Article  CAS  PubMed  Google Scholar 

  6. Dennis LK, Lynch CF, Torner JC . Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60): 78–83.

    Article  Google Scholar 

  7. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14 (11 Part 1): 2563–2568.

    Article  CAS  PubMed  Google Scholar 

  8. Eskdale J, Kube D, Tesch H, Gallagher G . Mapping of the human IL-10 gene and further characterisation of the 5′ flanking sequence. Immunogenetics 1997; 46: 120–128.

    Article  CAS  PubMed  Google Scholar 

  9. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA . Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. World J Urol 2008; 19: 119–124.

    Google Scholar 

  10. Crawley E, Woo P, Isenberg DA . Single nucleotide polymorphic haplotypes of the interleukin-10 5′ flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2017–2018.

    Article  CAS  PubMed  Google Scholar 

  11. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV . An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1–8.

    Article  CAS  PubMed  Google Scholar 

  12. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193–1201.

    Article  CAS  PubMed  Google Scholar 

  13. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS . An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 2005; 173: 709–712.

    Article  CAS  PubMed  Google Scholar 

  14. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007; 56: 371–379.

    Article  CAS  PubMed  Google Scholar 

  15. Howell WM, Rose-Zerilli MJ . Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006; 5: 143–149.

    Article  CAS  PubMed  Google Scholar 

  16. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525–4530.

    Article  CAS  PubMed  Google Scholar 

  17. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369–3372.

    CAS  PubMed  Google Scholar 

  18. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC et al. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 2007; 43: 472–475.

    Article  CAS  PubMed  Google Scholar 

  19. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008; 29: 573–578.

    Article  CAS  PubMed  Google Scholar 

  20. Omrani MD, Bazargani S, Bageri M . Interlukin-10, interferon-γ and tumor necrosis factor-α genes variation in prostate cancer and benign prostatic hyperplasia. Curr Urol 2009; 2: 175–180.

    Article  Google Scholar 

  21. Wang MH, Helzlsouer KJ, Smith MW, HoffmanBolton JA, Clipp SL, Grinberg V et al. Association of IL10 and other immune response-and obesity-related genes with prostate cancer in CLUE II. Prostate 2009; 69: 874–885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN et al. IL-10 1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009; 27: 389–396.

    Article  CAS  PubMed  Google Scholar 

  23. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 2010; 70: 341–352.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu J, Song B, Bai X, Liu W, Li Z, Wang J et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010; 10: 456.

    Article  PubMed  PubMed Central  Google Scholar 

  25. DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.

    Article  CAS  PubMed  Google Scholar 

  26. Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.

    CAS  PubMed  Google Scholar 

  27. Barba M, Yang L, Schunemann HJ, Sperati F, Grioni S, Stranges S et al. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res 2009; 28: 135.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ahirwar D, Mandhani A, Mittal RD . Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res 2009; 40: 97–102.

    Article  CAS  PubMed  Google Scholar 

  29. Howell WM, Turner SJ, Bateman AC, Theaker JM . IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2: 25–31.

    Article  CAS  PubMed  Google Scholar 

  30. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX et al. Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1525–1532.

    Article  CAS  PubMed  Google Scholar 

  31. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006; 176: 1012–1016.

    Article  PubMed  Google Scholar 

  32. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO et al. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 2009; 30: 1358–1362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947–956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY . Berberine suppresses inflammatory agents-induced interleukin-1β and tumor necrosis factor-α productions via the inhibition of IκB degradation in human lung cells. Pharmacol Res 2007; 56: 193–201.

    Article  CAS  PubMed  Google Scholar 

  35. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23: 3526–3535.

    Article  CAS  PubMed  Google Scholar 

  36. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822–827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. ElsasserBeile U, Kolble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Biol 1998; 19: 470–476.

    Article  CAS  Google Scholar 

  38. Richardsen E, Uglehus RD, Due J, Busch C, Busund LT . COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and Ki67. Cancer Epidemiol 2010; 34: 316–322.

    Article  CAS  PubMed  Google Scholar 

  39. Ioannidis JP . Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281–286.

    Article  CAS  PubMed  Google Scholar 

  40. Dickersin K, Min YI, Meinert CL . Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374–378.

    Article  CAS  PubMed  Google Scholar 

  41. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR . Publication bias in clinical research. Lancet 1991; 337: 867–872.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    N Shao, B Xu, Y-y Mi & L-x Hua

Authors
  1. N Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y-y Mi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L-x Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L-x Hua.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shao, N., Xu, B., Mi, Yy. et al. IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 14, 129–135 (2011). https://doi.org/10.1038/pcan.2011.6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.6

Keywords

This article is cited by

Search

Advanced search

Quick links